RxDoctor Payments Data

Dennis Debernardis, DO

Orthopaedic Surgery · Jersey City, NJNPI 1508396276

Payments from drug & device makers

$31,306in general payments, 2019–2025

Across 91 payments — averaging $344.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$12K
  • Medical Device Business Services, Inc.$5K
  • Encore Medical, LP$4K
  • Arthrex$2K
  • Liberty Surgical Inc.$2K
  • Stryker$2K
  • plus $5K from 7 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$1,5005%
  • Travel & lodging$9,90132%
  • Food & beverage$4,00513%
  • Education$15,60050%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew4$12,192
Medical Device Business Services, Inc.28$5,203
Encore Medical, LP8$3,566
Arthrex6$2,332
Liberty Surgical Inc.6$1,931
Stryker15$1,581
Tigon Medical LLC3$1,497
Legacy Ortho LLC1$1,200
Johnson & Johnson7$702
Suvon Surgical LLC7$510
Linvatec Corporation4$457
Pacira Pharmaceuticals Incorporated1$122
Dynasplint Systems Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,306 in reported general payments places this provider in the 85th percentile of 587 orthopaedic surgery providers in New Jersey.

See all orthopaedic surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$24,157
Medicare patients
70
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam20$23

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →